Syngene International has announced its second quarter results. The Company posted quarterly total revenue of Rs 533 Cr compared to Rs 485 Cr in the corresponding quarter of last year.

EBITDA for the quarter was up 6% to Rs. 169 Cr while PAT was up 2% to Rs. 84 Cr.

Commenting on the results, Jonathan Hunt, Managing Director and Chief Executive Officer - Syngene International Limited, said: “The second quarter saw a positive return to growth following a muted first quarter that was impacted by COVID-19, with second quarter revenue from operations growing 12% year-on-year and a PAT growth of 2%. This result reflects a robust operating performance as we have adapted to the COVID-19 situation. We are at near normal operating levels with all our scientists working on site with proper protective measures.

We are happy to continue to support the global health community in the fight against COVID-19 through our dedicated RT PCR testing laboratory, our research efforts and by developing and supplying reagents and oligonucleotides to diagnostic kit manufacturers."